Gilead to buy Immunomedics in $21 billion deal By Reuters


© Reuters. FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen during the outbreak of the coronavirus disease (COVID-19), in California

(Reuters) – Gilead Sciences Inc (O:) will acquire biopharmaceutical company Immunomedics Inc (O:) for $21 billion in a deal that would further expand Gilead’s portfolio of cancer treatments, the companies said in a statement on Sunday.

The deal provides Gilead access to Immunomedics’ breast cancer treatment drug, Trodelvy, which was granted an accelerated FDA approval in April.

Gilead said it would issue a tender offer to buy all the outstanding shares of Immunomedics for $88 per share in cash.

The offer will be funded through $15 billion in cash on hand, as well about $6 billion in newly issued debt, according to the statement.

The transaction is expected to close in the fourth quarter of 2020, the companies said.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Be the first to comment

Leave a Reply

Your email address will not be published.


*